Loading…

Next Generation Weight Loss Drugs for the Prevention of Cancer?

Background: Western populations are losing the battle over healthy weight management, and excess body weight is a notable cancer risk factor at the population level. There is ongoing interest in pharmacological interventions aimed at promoting weight loss, including GLP-1 receptor agonists (GLP-1RA)...

Full description

Saved in:
Bibliographic Details
Published in:Cancer control 2024-01, Vol.31, p.10732748241241158-10732748241241158
Main Authors: Carbonell, Chantelle, Mathew Stephen, Mariet, Ruan, Yibing, Warkentin, Matthew T., Brenner, Darren R.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c429t-ced0f8e705516486c2ba239c24d7f0c3755034e4c6563db1ba9273062ad5c8d33
container_end_page 10732748241241158
container_issue
container_start_page 10732748241241158
container_title Cancer control
container_volume 31
creator Carbonell, Chantelle
Mathew Stephen, Mariet
Ruan, Yibing
Warkentin, Matthew T.
Brenner, Darren R.
description Background: Western populations are losing the battle over healthy weight management, and excess body weight is a notable cancer risk factor at the population level. There is ongoing interest in pharmacological interventions aimed at promoting weight loss, including GLP-1 receptor agonists (GLP-1RA), which may be a useful tool to stem the rising tide of obesity-related cancers. Purpose: To investigate the potential of next generation weight loss drugs (NGWLD) like GLP-1RA in population-level chemoprevention. Research Design: We used the OncoSim microsimulation tool to estimate the population-level reductions in obesity and the potentially avoidable obesity-related cancers in Canada over the next 25 years. Results: We estimated a total of 71 281 preventable cancers by 2049, with 36 235 and 35 046 cancers prevented for females and males, respectively. Among the 327 254 total projected cancer cases in 2049, 1.3% are estimated to be preventable through intervention with NGWLD. Conclusions: Pharmacologic intervention is not the ideal solution for the obesity-related cancer crisis. However, these agents and subsequent generations provide an additional tool to rapidly reduce body weight and adiposity in populations that have been extremely challenging to reduce weight with standard diet and exercise approaches. Additional research is needed around approaches to prevent initial weight gain and maintain long-term weight loss.
doi_str_mv 10.1177/10732748241241158
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_4755900f206b409cb8897ebd38f7b5da</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_10732748241241158</sage_id><doaj_id>oai_doaj_org_article_4755900f206b409cb8897ebd38f7b5da</doaj_id><sourcerecordid>3149771657</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-ced0f8e705516486c2ba239c24d7f0c3755034e4c6563db1ba9273062ad5c8d33</originalsourceid><addsrcrecordid>eNp1kV1rFDEUhkNR2lr9Ab0pA954M_XkO7kqZdVaWLQXFS9DJjmznWV30iYzRf-9abdWUIRAQvKc5yR5CTmmcEqp1u8paM60MEzQOqg0e-SQSqZaxqV9Udf1vH0ADsirUtYADAQX--SAG0mVFuyQnH3BH1NzgSNmPw1pbL7jsLqZmmUqpfmQ51Vp-pSb6Qabq4z3OD5CqW8WfgyYz16Tl73fFHzzNB-Rb58-Xi8-t8uvF5eL82UbBLNTGzBCb1CDrI2FUYF1nnEbmIi6h8C1lMAFiqCk4rGjnbdMc1DMRxlM5PyIXO68Mfm1u83D1uefLvnBPW6kvHI-T0PYoBNVZgF6BqoTYENnjNXYRW563cnoq-vdznWb092MZXLboQTcbPyIaS6OWS0AhBSqom__QtdpzmN9qeNUWK2pkrpSdEeFXL8tY_98QQruISn3T1K15uTJPHdbjM8Vv6OpwOkOKH6Ff9r-3_gLM3yXTg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3149771657</pqid></control><display><type>article</type><title>Next Generation Weight Loss Drugs for the Prevention of Cancer?</title><source>Publicly Available Content Database</source><source>Sage Journals GOLD Open Access 2024</source><source>PubMed Central</source><creator>Carbonell, Chantelle ; Mathew Stephen, Mariet ; Ruan, Yibing ; Warkentin, Matthew T. ; Brenner, Darren R.</creator><creatorcontrib>Carbonell, Chantelle ; Mathew Stephen, Mariet ; Ruan, Yibing ; Warkentin, Matthew T. ; Brenner, Darren R.</creatorcontrib><description>Background: Western populations are losing the battle over healthy weight management, and excess body weight is a notable cancer risk factor at the population level. There is ongoing interest in pharmacological interventions aimed at promoting weight loss, including GLP-1 receptor agonists (GLP-1RA), which may be a useful tool to stem the rising tide of obesity-related cancers. Purpose: To investigate the potential of next generation weight loss drugs (NGWLD) like GLP-1RA in population-level chemoprevention. Research Design: We used the OncoSim microsimulation tool to estimate the population-level reductions in obesity and the potentially avoidable obesity-related cancers in Canada over the next 25 years. Results: We estimated a total of 71 281 preventable cancers by 2049, with 36 235 and 35 046 cancers prevented for females and males, respectively. Among the 327 254 total projected cancer cases in 2049, 1.3% are estimated to be preventable through intervention with NGWLD. Conclusions: Pharmacologic intervention is not the ideal solution for the obesity-related cancer crisis. However, these agents and subsequent generations provide an additional tool to rapidly reduce body weight and adiposity in populations that have been extremely challenging to reduce weight with standard diet and exercise approaches. Additional research is needed around approaches to prevent initial weight gain and maintain long-term weight loss.</description><identifier>ISSN: 1073-2748</identifier><identifier>EISSN: 1526-2359</identifier><identifier>DOI: 10.1177/10732748241241158</identifier><identifier>PMID: 38516742</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adipose tissue ; Anti-Obesity Agents - therapeutic use ; Body weight ; Body weight loss ; Cancer ; Drug development ; Female ; Humans ; Male ; Neoplasms - epidemiology ; Neoplasms - prevention &amp; control ; Obesity ; Obesity - complications ; Obesity - epidemiology ; Research design ; Risk Factors ; Weight control ; Weight Loss</subject><ispartof>Cancer control, 2024-01, Vol.31, p.10732748241241158-10732748241241158</ispartof><rights>The Author(s) 2024</rights><rights>The Author(s) 2024. This work is licensed under the Creative Commons Attribution License https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c429t-ced0f8e705516486c2ba239c24d7f0c3755034e4c6563db1ba9273062ad5c8d33</cites><orcidid>0009-0004-6384-3424</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/10732748241241158$$EPDF$$P50$$Gsage$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3149771657?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,21966,25753,27853,27924,27925,37012,37013,44590,44945,45333</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38516742$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carbonell, Chantelle</creatorcontrib><creatorcontrib>Mathew Stephen, Mariet</creatorcontrib><creatorcontrib>Ruan, Yibing</creatorcontrib><creatorcontrib>Warkentin, Matthew T.</creatorcontrib><creatorcontrib>Brenner, Darren R.</creatorcontrib><title>Next Generation Weight Loss Drugs for the Prevention of Cancer?</title><title>Cancer control</title><addtitle>Cancer Control</addtitle><description>Background: Western populations are losing the battle over healthy weight management, and excess body weight is a notable cancer risk factor at the population level. There is ongoing interest in pharmacological interventions aimed at promoting weight loss, including GLP-1 receptor agonists (GLP-1RA), which may be a useful tool to stem the rising tide of obesity-related cancers. Purpose: To investigate the potential of next generation weight loss drugs (NGWLD) like GLP-1RA in population-level chemoprevention. Research Design: We used the OncoSim microsimulation tool to estimate the population-level reductions in obesity and the potentially avoidable obesity-related cancers in Canada over the next 25 years. Results: We estimated a total of 71 281 preventable cancers by 2049, with 36 235 and 35 046 cancers prevented for females and males, respectively. Among the 327 254 total projected cancer cases in 2049, 1.3% are estimated to be preventable through intervention with NGWLD. Conclusions: Pharmacologic intervention is not the ideal solution for the obesity-related cancer crisis. However, these agents and subsequent generations provide an additional tool to rapidly reduce body weight and adiposity in populations that have been extremely challenging to reduce weight with standard diet and exercise approaches. Additional research is needed around approaches to prevent initial weight gain and maintain long-term weight loss.</description><subject>Adipose tissue</subject><subject>Anti-Obesity Agents - therapeutic use</subject><subject>Body weight</subject><subject>Body weight loss</subject><subject>Cancer</subject><subject>Drug development</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Neoplasms - epidemiology</subject><subject>Neoplasms - prevention &amp; control</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - epidemiology</subject><subject>Research design</subject><subject>Risk Factors</subject><subject>Weight control</subject><subject>Weight Loss</subject><issn>1073-2748</issn><issn>1526-2359</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kV1rFDEUhkNR2lr9Ab0pA954M_XkO7kqZdVaWLQXFS9DJjmznWV30iYzRf-9abdWUIRAQvKc5yR5CTmmcEqp1u8paM60MEzQOqg0e-SQSqZaxqV9Udf1vH0ADsirUtYADAQX--SAG0mVFuyQnH3BH1NzgSNmPw1pbL7jsLqZmmUqpfmQ51Vp-pSb6Qabq4z3OD5CqW8WfgyYz16Tl73fFHzzNB-Rb58-Xi8-t8uvF5eL82UbBLNTGzBCb1CDrI2FUYF1nnEbmIi6h8C1lMAFiqCk4rGjnbdMc1DMRxlM5PyIXO68Mfm1u83D1uefLvnBPW6kvHI-T0PYoBNVZgF6BqoTYENnjNXYRW563cnoq-vdznWb092MZXLboQTcbPyIaS6OWS0AhBSqom__QtdpzmN9qeNUWK2pkrpSdEeFXL8tY_98QQruISn3T1K15uTJPHdbjM8Vv6OpwOkOKH6Ff9r-3_gLM3yXTg</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Carbonell, Chantelle</creator><creator>Mathew Stephen, Mariet</creator><creator>Ruan, Yibing</creator><creator>Warkentin, Matthew T.</creator><creator>Brenner, Darren R.</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><general>SAGE Publishing</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0009-0004-6384-3424</orcidid></search><sort><creationdate>20240101</creationdate><title>Next Generation Weight Loss Drugs for the Prevention of Cancer?</title><author>Carbonell, Chantelle ; Mathew Stephen, Mariet ; Ruan, Yibing ; Warkentin, Matthew T. ; Brenner, Darren R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-ced0f8e705516486c2ba239c24d7f0c3755034e4c6563db1ba9273062ad5c8d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adipose tissue</topic><topic>Anti-Obesity Agents - therapeutic use</topic><topic>Body weight</topic><topic>Body weight loss</topic><topic>Cancer</topic><topic>Drug development</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Neoplasms - epidemiology</topic><topic>Neoplasms - prevention &amp; control</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - epidemiology</topic><topic>Research design</topic><topic>Risk Factors</topic><topic>Weight control</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carbonell, Chantelle</creatorcontrib><creatorcontrib>Mathew Stephen, Mariet</creatorcontrib><creatorcontrib>Ruan, Yibing</creatorcontrib><creatorcontrib>Warkentin, Matthew T.</creatorcontrib><creatorcontrib>Brenner, Darren R.</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Directory of Open Access Journals</collection><jtitle>Cancer control</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carbonell, Chantelle</au><au>Mathew Stephen, Mariet</au><au>Ruan, Yibing</au><au>Warkentin, Matthew T.</au><au>Brenner, Darren R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Next Generation Weight Loss Drugs for the Prevention of Cancer?</atitle><jtitle>Cancer control</jtitle><addtitle>Cancer Control</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>31</volume><spage>10732748241241158</spage><epage>10732748241241158</epage><pages>10732748241241158-10732748241241158</pages><issn>1073-2748</issn><eissn>1526-2359</eissn><abstract>Background: Western populations are losing the battle over healthy weight management, and excess body weight is a notable cancer risk factor at the population level. There is ongoing interest in pharmacological interventions aimed at promoting weight loss, including GLP-1 receptor agonists (GLP-1RA), which may be a useful tool to stem the rising tide of obesity-related cancers. Purpose: To investigate the potential of next generation weight loss drugs (NGWLD) like GLP-1RA in population-level chemoprevention. Research Design: We used the OncoSim microsimulation tool to estimate the population-level reductions in obesity and the potentially avoidable obesity-related cancers in Canada over the next 25 years. Results: We estimated a total of 71 281 preventable cancers by 2049, with 36 235 and 35 046 cancers prevented for females and males, respectively. Among the 327 254 total projected cancer cases in 2049, 1.3% are estimated to be preventable through intervention with NGWLD. Conclusions: Pharmacologic intervention is not the ideal solution for the obesity-related cancer crisis. However, these agents and subsequent generations provide an additional tool to rapidly reduce body weight and adiposity in populations that have been extremely challenging to reduce weight with standard diet and exercise approaches. Additional research is needed around approaches to prevent initial weight gain and maintain long-term weight loss.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>38516742</pmid><doi>10.1177/10732748241241158</doi><orcidid>https://orcid.org/0009-0004-6384-3424</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1073-2748
ispartof Cancer control, 2024-01, Vol.31, p.10732748241241158-10732748241241158
issn 1073-2748
1526-2359
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_4755900f206b409cb8897ebd38f7b5da
source Publicly Available Content Database; Sage Journals GOLD Open Access 2024; PubMed Central
subjects Adipose tissue
Anti-Obesity Agents - therapeutic use
Body weight
Body weight loss
Cancer
Drug development
Female
Humans
Male
Neoplasms - epidemiology
Neoplasms - prevention & control
Obesity
Obesity - complications
Obesity - epidemiology
Research design
Risk Factors
Weight control
Weight Loss
title Next Generation Weight Loss Drugs for the Prevention of Cancer?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A33%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Next%20Generation%20Weight%20Loss%20Drugs%20for%20the%20Prevention%20of%20Cancer?&rft.jtitle=Cancer%20control&rft.au=Carbonell,%20Chantelle&rft.date=2024-01-01&rft.volume=31&rft.spage=10732748241241158&rft.epage=10732748241241158&rft.pages=10732748241241158-10732748241241158&rft.issn=1073-2748&rft.eissn=1526-2359&rft_id=info:doi/10.1177/10732748241241158&rft_dat=%3Cproquest_doaj_%3E3149771657%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c429t-ced0f8e705516486c2ba239c24d7f0c3755034e4c6563db1ba9273062ad5c8d33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3149771657&rft_id=info:pmid/38516742&rft_sage_id=10.1177_10732748241241158&rfr_iscdi=true